A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.

PHASE1CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

March 15, 2004

Primary Completion Date

April 26, 2005

Study Completion Date

April 26, 2005

Conditions

Malaria

Interventions

BIOLOGICAL

RTS,S/AS02D and RTS,S/AS02A

Trial Locations (1)

GSK Investigational Site, Maputo